|
2
Votes
vote
AVI BioPharma Phase 1 Proof of Concept and Safety Data for AVI-4658 in Duchenne Muscular Dystrophy Featured in Lancet NeurologyAVI-4658 Demonstrates Compelling Proof of Concept and Safety Profile for Pediatric Patients With DMD; Findings Support Progression to Current Systemic Use Trial ... |

